You have free access to this content

Cancer

Cover image for Vol. 119 Issue 1

1 January 2013

Volume 119, Issue 1

Pages 1–246

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  2. Editorials

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
      Cancer care planning and quality improvement: 2 for the price of 1? (pages 4–6)

      Sofia F. Garcia and Patricia A. Ganz

      Article first published online: 29 NOV 2012 | DOI: 10.1002/cncr.27861

      This editorial comments on 2 companion articles that present the preliminary results of the American Society of Clinical Oncology (ASCO) breast cancer registry (BCR) pilot program. The ASCO BCR demonstrates how registry data can be collected prospectively for quality assessment purposes as well as the creation of treatment and survivorship care plans in a way that is acceptable to oncology clinicians and patients.

  3. Original Articles

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer (pages 7–15)

      Ana M. Gonzalez-Angulo, Huiqin Chen, Meghan S. Karuturi, Mariana Chavez-MacGregor, Spyrus Tsavachidis, Funda Meric-Bernstam, Kim-Anh Do, Gabriel N. Hortobagyi, Patricia A. Thompson, Gordon B. Mills, Melissa L. Bondy and George R. Blumenschein Jr

      Article first published online: 26 JUN 2012 | DOI: 10.1002/cncr.27608

      High copy numbers of either Mesenchymal-Epithelial Transition Factor Gene (MET) or catalytic subunit of phosphoinositide-3-kinase (PIK3CA) were associated with poorer prognostic features and triple receptor-negative disease. Coamplification was frequent. Patients with tumors with a high MET copy number tended to have a worse recurrence-free survival.

    2. You have free access to this content
      Predictors of locoregional outcome in patients receiving neoadjuvant therapy and postmastectomy radiation (pages 16–25)

      Jean L. Wright, Cristiane Takita, Isildinha M. Reis, Wei Zhao, Kunal Saigal, Aaron Wolfson, Arnold Markoe, Mecker Moller and Judith Hurley

      Article first published online: 26 JUN 2012 | DOI: 10.1002/cncr.27717

      In a cohort of patients with stage II and III breast cancer receiving neoadjuvant therapy (NAT) and postmastectomy radiation, stage at presentation, combined receptor status, pathologic response to NAT, and omission of the supraclavicular field are identified as risk factors for locoregional recurrence after NAT.

    3. Gastrointestinal Disease
      You have free access to this content
      Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival (pages 26–35)

      Thilo Sprenger, Lena-Christin Conradi, Tim Beissbarth, Heiko Ermert, Kia Homayounfar, Peter Middel, Josef Rüschoff, Hendrik A. Wolff, Philipp Schüler, B. Michael Ghadimi, Claus Rödel, Heinz Becker, Franz Rödel and Torsten Liersch

      Article first published online: 26 JUN 2012 | DOI: 10.1002/cncr.27703

      The authors study the impact of CD133 (cluster of differentiation 133; a transmembrane glycoprotein also known as Prominin or PROM1) expression levels in pretreatment and post-treatment tumor specimens from 126 patients with locally advanced rectal cancers undergoing multimodal therapy with preoperative radiochemotherapy (RCT) and curative surgery. The results demonstrate that an enrichment of CD133-expressing cancer cells during RCT, and not absolute CD133 expression levels before and after RCT, can identify patients who are at higher risk of distant relapse and poor survival and may qualify for intensified after-care programs and adjuvant therapy.

    4. You have free access to this content
      Gastroenteric neuroendocrine neoplasms classification: Comparison of prognostic models (pages 36–44)

      Anna Dolcetta-Capuzzo, Valentina Villa, Luca Albarello, Giulia M. Franchi, Marco Gemma, Marina Scavini, Saverio Di Palo, Elena Orsenigo, Emanuele Bosi, Claudio Doglioni and Marco F. Manzoni

      Article first published online: 28 JUN 2012 | DOI: 10.1002/cncr.27716

      The 2010 World Health Organization classification, the European Neuroendocrine Tumor Society (ENETS) grading, and the ENETS staging systems all are valid instruments for the prognostic assessment of gastroenteric neuroendocrine neoplasms. ENETS TNM-based staging is the best available choice for prognostic evaluation, both alone and in association with other classifications.

    5. You have free access to this content
      Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer (pages 45–51)

      Makoto Shinoto, Shigeru Yamada, Shigeo Yasuda, Hiroshi Imada, Yoshiyuki Shioyama, Hiroshi Honda, Tadashi Kamada, Hirohiko Tsujii, Hiromitsu Saisho and Working Group for Pancreas Cancer

      Article first published online: 28 JUN 2012 | DOI: 10.1002/cncr.27723

      Patients who receive preoperative, short-course carbon-ion radiotherapy experience no dose-limiting toxicity. Preoperative, short-course carbon-ion radiotherapy followed by surgery is feasible and tolerable without unacceptable morbidity in the treatment of resectable pancreatic cancer.

    6. Genitourinary Disease
      You have free access to this content
      Elective irradiation of pelvic lymph nodes during postprostatectomy salvage radiotherapy (pages 52–60)

      Drew Moghanaki, Bridget F. Koontz, Jeremy D. Karlin, Wen Wan, Nitai Mukhopadhay, Michael P. Hagan and Mitchell S. Anscher

      Article first published online: 26 JUN 2012 | DOI: 10.1002/cncr.27712

      The investigators report the outcomes of 247 prostate cancer patients with postprostatectomy biochemical failure who received salvage radiotherapy according to a paradigm of either targeting the whole pelvis or limiting treatment to the prostate bed at 2 separate institutions. Improved biochemical control was associated with larger treatment fields, a finding limited to patients with preradiotherapy prostate-specific antigen levels ≥0.4 ng/mL.

    7. You have free access to this content
      C-X-C chemokine receptor 7 : A functionally associated molecular marker for bladder cancer (pages 61–71)

      Travis J. Yates, Judith Knapp, Miguel Gosalbez, Soum D. Lokeshwar, Christopher S. Gomez, Anaid Benitez, Obi O. Ekwenna, Ezekiel E. Young, Murugesan Manoharan and Vinata B. Lokeshwar

      Article first published online: 26 JUN 2012 | DOI: 10.1002/cncr.27661

      This is the first study that shows C-X-C chemokine receptor 7 (CXCR7) expression is elevated in bladder cancer tissues and exfoliated urothelial cells and correlates with aggressive phenotype with high accuracy. CXCR7 promotes bladder cancer cell proliferation, motility, and survival, plausibly through epidermal growth factor receptor and/or Akt signaling.

    8. Head and Neck Disease
      You have free access to this content
      A microRNA expression signature for the prognosis of oropharyngeal squamous cell carcinoma (pages 72–80)

      Ge Gao, Hiram A. Gay, Rebecca D. Chernock, Tian R. Zhang, Jingqin Luo, Wade L. Thorstad, James S. Lewis Jr and Xiaowei Wang

      Article first published online: 26 JUN 2012 | DOI: 10.1002/cncr.27696

      A microRNA (miRNA) signature was found to be prognostic of oropharyngeal cancer, independent of common clinical features or human papillomavirus (HPV) status. Moreover, HPV-related miRNAs were identified that may help to characterize HPV-induced cancers.

    9. You have free access to this content
      An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center : A staging system in need of repair (pages 81–89)

      Kristina R. Dahlstrom, Gabriel Calzada, Jennifer D. Hanby, Adam S. Garden, Bonnie S. Glisson, Guojun Li, Dianna B. Roberts, Randal S. Weber and Erich M. Sturgis

      Article first published online: 26 JUN 2012 | DOI: 10.1002/cncr.27727

      The overall survival of patients with squamous cell carcinoma of the oropharynx has improved significantly over the past 5 decades. Tumor classification and lymph node status are the most important factors for patients who were diagnosed between 1955 and 1994; and smoking status, T classification, age, and tumor site are the most important factors for patients who were diagnosed between 1995 and 2004. The current TNM staging system does not adequately predict survival in the 1995 to 2004 cohort and indicates the need to incorporate other factors, such as smoking and human papillomavirus status, into the staging system.

    10. Hematologic Malignancies
      You have free access to this content
      Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia : Results of Cancer and Leukemia Group B Study 19802 (pages 90–98)

      Wendy Stock, Jeffrey L. Johnson, Richard M. Stone, Jonathan E. Kolitz, Bayard L. Powell, Meir Wetzler, Peter Westervelt, Guido Marcucci, Daniel J. DeAngelo, James W. Vardiman, Diane McDonnell, Krzysztof Mrózek, Clara D. Bloomfield and Richard A. Larson

      Article first published online: 28 JUN 2012 | DOI: 10.1002/cncr.27617

      Dose intensification of daunorubicin and cytarabine during induction and consolidation therapy for adult patients with newly diagnosed acute lymphoblastic leukemia is tolerable but does not result in improved disease-free or overall survival compared with historic controls in Cancer and Leukemia Group B Study 19801. The administration of central nervous system prophylaxis with systemic methotrexate (intrathecal, oral, and intravenous) for central nervous system prophylaxis permits the omission of central nervous system irradiation.

    11. You have free access to this content
      Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma : An analysis of clinical presentation and outcome in 144 patients (pages 99–106)

      Andreas Heilgeist, Fabienne McClanahan, Anthony D. Ho and Mathias Witzens-Harig

      Article first published online: 26 JUN 2012 | DOI: 10.1002/cncr.27704

      The Follicular Lymphoma International Prognostic Index (FLIPI) score has strong prognostic value in marginal zone lymphoma. Patients with low-risk or intermediate-risk FLIPI scores have an excellent prognosis, whereas patients with poor-risk FLIPI scores may be candidates for novel treatment approaches.

    12. You have free access to this content
      Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients (pages 107–114)

      Mauricette Michallet, Karine Goldet, Mohamad Sobh, Stéphane Morisset, Youcef Chelghoum, Xavier Thomas, Fiorenza Barraco, Sophie Ducastelle, Hélène Labussière, Catherine Renzullo, Carole Paillet, Christine Pivot, Perrine Badol-Van Straaten, Angelique Denis, Anne Termoz, Marie Detrait, Franck-Emmanuel Nicolini and Isabelle Jaisson-Hot

      Article first published online: 28 JUN 2012 | DOI: 10.1002/cncr.27686

      In acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients, erythropoiesis-stimulating agents have a clinical and economic benefit on quality of life, hemoglobin recovery, and lead to a significant reduction of red blood cell transfusions with no effect on survival. Specific guidelines on erythropoiesis-stimulating agent use in these 2 populations are needed.

    13. You have free access to this content
      Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia (pages 115–125)

      Yingmei Zhang, Zhuo Zhang, Jinmei Li, Limin Li, Xueying Han, Lina Han, Longhu Hu, Shuye Wang, Yanhong Zhao, Xiaoxia Li, Ying Zhang, Shengjin Fan, Chengfang Lv, Yinghua Li, Yanhua Su, Hui Zhao, Xin Zhang and Jin Zhou

      Article first published online: 28 AUG 2012 | DOI: 10.1002/cncr.27650

      This study shows that the single-agent arsenic trioxide regimens have a high antileukemic efficacy and low toxicity, and can be used as first-line treatment for elderly patients with de novo acute promyelocytic leukemia.

    14. Hepatobiliary Disease
      You have free access to this content
      Hepatitis B virus surface antigen-negative and hepatitis C virus antibody-negative hepatocellular carcinoma : Clinical characteristics, outcome, and risk factors for early and late intrahepatic recurrence after resection (pages 126–135)

      Tao Li, Lun-Xiu Qin, Xiao Gong, Jian Zhou, Hui-Chuan Sun, Shuang-Jian Qiu, Qing-Hai Ye, Lu Wang and Jia Fan

      Article first published online: 26 JUN 2012 | DOI: 10.1002/cncr.27697

      Patients with hepatitis B virus surface antigen (HBsAg)-negative/hepatitis C virus antibody (HCVAb)-negative hepatocellular carcinoma (NBNC-HCC) have clinicopathologic characteristics and prognostic factors that differ from those in patients with HBsAg-positive/HCVAb-negative HCC. Compared with men, women who have NBNC-HCC have a poorer prognosis, and it may be worthwhile to evaluate estrogen administration for the maintenance of sex hormone balance and to improve these poor outcomes.

    15. You have free access to this content
      Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma (pages 136–142)

      Joo Ho Lee, Young-Hwa Chung, Jeong A. Kim, Ju Hyun Shim, Danbi Lee, Han Chu Lee, Eun-Soon Shin, Jung Hwan Yoon, Byung Ik Kim, Si Hyun Bae, Kwang Cheol Koh and Neung-Hwa Park

      Article first published online: 26 JUN 2012 | DOI: 10.1002/cncr.27705

      It has been suggested that Asian patients with hepatocellular carcinoma have increased susceptibility to hand-foot skin reaction (HFSR) related to sorafenib therapy. Differences in the incidence of HFSR may be caused by ethnic differences in genetic polymorphisms of the genes, tumor necrosis factor-alpha (TNF-α), vascular endothelial growth factor (VEGF), and uridine diphosphate glucuronosyltransferase 1 family-polypeptide A9 (UGT1A9), especially in relation to the expression of serum TNF-α after sorafenib therapy.

    16. Discipline

      Clinical Trials
      You have free access to this content
      Who should be included in a clinical trial of screening for bladder cancer? : A decision analysis of data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (pages 143–149)

      Andrew J. Vickers, Caroline Bennette, Adam S. Kibel, Amanda Black, Grant Izmirlian, Andrew J. Stephenson and Bernard Bochner

      Article first published online: 26 JUN 2012 | DOI: 10.1002/cncr.27692

      Different eligibility criteria for a screening trial of patients with bladder cancer were compared using decision-analytic techniques. The optimal high-risk subgroup for screening can be defined in terms of a risk score, based on age and sex as well as smoking and family histories.

    17. Disparities Research
      You have free access to this content
      Impact of race and ethnicity on features and outcome of ductal carcinoma in situ of the breast (pages 150–157)

      Adele A. Bailes, Henry M. Kuerer, Sara A. Lari, Lovell A. Jones and Abenaa M. Brewster

      Article first published online: 26 JUN 2012 | DOI: 10.1002/cncr.27707

      In this largest reported, single-institution analysis to date of the impact of race and ethnicity on the biologic features and outcome variables of patients with ductal carcinoma in situ, although age at presentation and positive estrogen receptor status vary among different ethnic groups, significant disparities in the histopathologic features, presentation, and outcomes of patients with ductal carcinoma in situ are not observed.

    18. Outcomes Research
      You have free access to this content
      Implementing a breast cancer registry and treatment plan/summary program in clinical practice: A pilot program (pages 158–163)

      Ann H. Partridge, Virginia W. Norris, Victoria S. Blinder, Bruce A. Cutter, Michael T. Halpern, Jennifer Malin, Michael N. Neuss, Antonio C. Wolff and on behalf of the ASCO Breast Cancer Registry Pilot Steering Group

      Article first published online: 29 NOV 2012 | DOI: 10.1002/cncr.27625

      This multicenter pilot study evaluates the feasibility of prospective data collection for quality assessment and improvement in daily clinical practice. The findings show that data collection incorporated into clinical practice is feasible and acceptable to clinicians and staff.

    19. You have free access to this content
      Patient perspectives on breast cancer treatment plan and summary documents in community oncology care : A pilot program (pages 164–172)

      Victoria S. Blinder, Virginia W. Norris, Nancy W. Peacock, Jennifer J. Griggs, David P. Harrington, Anne Moore, Richard L. Theriault, Ann H. Partridge and on behalf of the American Society of Clinical Oncology Breast Cancer Registry Pilot Steering Group

      Article first published online: 29 NOV 2012 | DOI: 10.1002/cncr.27856

      Breast cancer survivors express high levels of satisfaction with the integration of treatment plan and summary documents into their clinical care. Participants recommended that practices continue to provide these documents to their patients.

    20. Pathology
      You have free access to this content
      Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma (pages 173–181)

      Hao Xie, Wei Jiang, John Jiang, Yixin Wang, Richard Kim, Xiaobo Liu and Xiuli Liu

      Article first published online: 26 JUN 2012 | DOI: 10.1002/cncr.27715

      Predictive factors of adjuvant therapy are lacking in patients with resectable pancreatic adenocarcinoma. Evaluation of the predictive value of ribonucleotide reductase M1 (RRM1) expression in this study demonstrates that low expression of RRM1 predicts gemcitabine treatment effect and that high expression of RRM1 predicts nongemcitabine treatment effect (mainly chemoradiation).

    21. Pediatric Oncology
      You have free access to this content
      Is routine pelvic surveillance imaging necessary in patients with Wilms tumor? (pages 182–188)

      Sue C. Kaste, Samuel L. Brady, Brian Yee, Valerie J. McPherson, Robert A. Kaufman, Catherine A. Billups, Najat C. Daw and Alberto S. Pappo

      Article first published online: 26 JUN 2012 | DOI: 10.1002/cncr.27687

      Omitting pelvic computed tomography from the routine, off-therapy follow-up of patients with Wilms tumor saves an average 30% to 45% of the effective dose (when imaging at a 120-kilovolt peak) without compromising disease detection. The use of this modality in patients with high-risk features for pelvic recurrence or pelvic disease, such as age at diagnosis ≥48 months, higher stage disease (stage III), specimen weight >1000 g, positive tumor margins, capsular penetration, tumor spillage, or unfavorable histology, deserves investigation in prospective national clinical trials.

    22. Psychosocial Oncology
      You have free access to this content
      Patient decision aids for cancer treatment : Are there any alternatives? (pages 189–200)

      Gillian Spiegle, Eisar Al-Sukhni, Selina Schmocker, Anna R. Gagliardi, J. Charles Victor, Nancy N. Baxter and Erin D. Kennedy

      Article first published online: 18 JUL 2012 | DOI: 10.1002/cncr.27641

      This study showed that the effectiveness of decision support interventions, including question prompt lists and audiorecording of the consultation, is similar to patient decision aids. This is important because it may be that these less complex decision support interventions may be all that is necessary to achieve similar outcomes as patient decision aids for cancer treatment.

    23. You have free access to this content
      Psychosocial service use and unmet need among recently diagnosed adolescent and young adult cancer patients (pages 201–214)

      Brad J. Zebrack, Rebecca Block, Brandon Hayes-Lattin, Leanne Embry, Christine Aguilar, Kathleen A. Meeske, Yun Li, Melissa Butler and Steven Cole

      Article first published online: 28 JUN 2012 | DOI: 10.1002/cncr.27713

      Adolescents and young adults with cancer demonstrate biomedical risks and psychosocial issues distinct from those of younger children or older adult patients. The current findings suggest that substantial proportions of these patients are not getting their psychosocial care needs met.

    24. Quality of Life
      You have free access to this content
      Preferences for outcomes associated with decisions to undergo or forgo genetic testing for Lynch syndrome (pages 215–225)

      Miriam Kuppermann, Grace Wang, Shirley Wong, Amie Blanco, Peggy Conrad, Sanae Nakagawa, Jonathan Terdiman and Uri Ladabaum

      Article first published online: 11 JUL 2012 | DOI: 10.1002/cncr.27634

      A set of preference scores (utilities) were generated that can be used in cost-effectiveness analyses. On average, Lynch syndrome testing is associated with higher utilities than forgoing testing, but these preferences vary substantially, suggesting that many patients will not necessarily avail themselves of testing even if it is offered to them.

    25. Radiation Oncology
      You have free access to this content
      Leukoencephalopathy after whole-brain radiation therapy plus radiosurgery versus radiosurgery alone for metastatic lung cancer (pages 226–232)

      Edward A. Monaco III, Amir H. Faraji, Oren Berkowitz, Phillip V. Parry, Uri Hadelsberg, Hideyuki Kano, Ajay Niranjan, Douglas Kondziolka and L. Dade Lunsford

      Article first published online: 15 JUN 2012 | DOI: 10.1002/cncr.27504

      Whole-brain radiation therapy has been associated with neurocognitive dysfunction. Gamma Knife stereotactic radiosurgery as an upfront strategy for management of lung cancer brain metastases avoids white matter changes that have been correlated with whole-brain radiation toxicity.

    26. Translational Research
      You have free access to this content
      Clinical implications and diagnostic usefulness of correlation between soluble major histocompatibility complex class I chain-related molecule a and protumorigenic cytokines in pancreatic ductal adenocarcinoma (pages 233–244)

      Hye Won Chung, Sunphil Jang and Jong-Baeck Lim

      Article first published online: 26 JUN 2012 | DOI: 10.1002/cncr.27669

      Soluble major histocompatibility complex class I chain-related molecule A (sMICA) may be involved in tumor-associated angiogenesis and tumor growth by affecting corresponding cytokines as well as causing impairment of natural killer cell cytotoxicity in the development and progression of pancreatic ductal adenocarcinoma (PDAC). The results of this study will provide valuable information to develop new soluble biomarkers or therapeutic approaches in PDAC with respect to sMICA and dysregulated cytokines in PDAC.

  4. Correspondence

    1. Top of page
    2. CancerScope
    3. Editorials
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
      Circumcision unlikely to be associated with prostate cancer risk (page 245)

      Andrew E. Grulich and Claire M. Vajdic

      Article first published online: 28 JUN 2012 | DOI: 10.1002/cncr.27711

    2. You have free access to this content
      Reply to circumcision unlikely to be associated with prostate cancer risk (page 246)

      Jonathan L. Wright, Daniel W. Lin and Janet L. Stanford

      Article first published online: 28 JUN 2012 | DOI: 10.1002/cncr.27714

SEARCH

SEARCH BY CITATION